Friday 04 Jul, 2025 09:08 PM
Site map | Locate Us | Login
   Bank of Maharashtra's total deposits climb 14% YoY to Rs 3.05 lakh crore in Q1    GPT Infraprojects bags supply contract from Bangladesh-based Standard Engineers    Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States    India Ratings affirms ratings of Polyplex Corporation with 'stable' outlook    Nuvama Wealth Management Ltd leads losers in 'A' group    Crisil Ratings reaffirms ratings of GIC Housing Finance at 'AA+/A1+' with 'stable' outlook    Dreamfolks Services Ltd leads losers in 'B' group    Volumes spurt at Sapphire Foods India Ltd counter    Shriram Properties launches new project with Rs 350 crore revenue potential in South Bengaluru    Trent crashes as Q1 growth misses expectations    SBI Cards & Payment Services Ltd drops for fifth straight session    Ajanta Pharma Ltd spurts 1.6%, gains for third straight session    Bosch Ltd gains for third consecutive session    Glenmark Pharmaceuticals Ltd spurts 1.6%, rises for fifth straight session    AU SFB total deposits rises 31% YoY to Rs 1.27 lakh crore in Q1 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States
04-Jul-25   15:29 Hrs IST

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc.

The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.

According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24.

The scrip added 1.36% to end at Rs 1982.20 on the BSE today.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 42416863
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited